| Elisigen's AAV gene therapy NG101 demonstrated a strong 52-week safety profile and significantly reduced anti-VEGF injection burden with a single low-dose treatment in patients with wAMD. |
Read Original Article (English)
*Note: This link will redirect you to the original source in English.